Immunotherapy trials in mesothelioma — promising results, but don’t stop here

TY - JOUR

T1 - Immunotherapy trials in mesothelioma — promising results, but don’t stop here

AU - Nowak, Anna K.

AU - Forde, Patrick M.

N1 - Funding Information: The research of A.K.N. is supported by the National Health and Medical Research Council Centre for Research Excellence Grant. Funding Information: A.K.N. has been a paid consultant or adviser for Bayer, Boehringer Ingelheim, MSD and Roche; has been a consultant or adviser with fees to her institution for Atara, Douglas and Pharmabcine; has received travel funding from AstraZeneca and Boehringer Ingelheim; and her institution receives research funding to institution from AstraZeneca and Douglas Pharmaceuticals. P.M.F. has been an unpaid consultant or adviser for Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb (BMS), EMD Serono, Inivata, Janssen, Merck and Novartis, and his institution receives research funding from AstraZeneca, BMS, Corvus, Kyowa and Novartis.

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85074528834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074528834&partnerID=8YFLogxK

U2 - 10.1038/s41571-019-0291-4

DO - 10.1038/s41571-019-0291-4

M3 - Article

C2 - 31624358

AN - SCOPUS:85074528834

SN - 1759-4774

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

ER -